Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644079 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL4533808 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL4940047 | 0.83 | NPC1 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL31359169 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL12810135 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL31629792 | 0.80 | CYP2A6 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1CYP2A6 | |
| SCHEMBL2092834 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL2092831 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL18863765 | 0.79 | CYP2A6 (0.44) | SMN1; SMN2ALDH1A1HSD17B10MAPTPOLB | |
| SCHEMBL18540878 | 0.78 | NPC1 (0.58) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| CN-118420523-A | Pyridine derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2023218023-A1 | THIAZOLOARYL-METHYL SUBSTITUTED CYCLIC HYDRAZINE-N-CARBOXAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023008577-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | 国立大学法人神戸大学 | 2023-02-02 | — | — | WO | disclosed |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-29 | — | — | US | disclosed |
| CN-107108601-B | Glycosidase inhibitors | 阿森纽荣股份公司 | 2021-08-20 | — | — | CN | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| US-6893859-B2 | Epothilone derivatives and methods for making and using the same | KOSAN BIOSCIENCES, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050038086-A1 | Epothilone derivatives and methods for making and using the same | ASHLEY GARY (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-6589968-B2 | Anticancer, antiproliferative and antiarthritic agents | KOSAN BIOSCIENCES, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20030045711-A1 | Epothilone derivatives and methods for making and using the same | KOSAN BIOSCIENCES, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20020193361-A1 | Epothilone derivatives and methods for making and using the same | KOSAN BIOSCIENCES, INC. | 2002-12-19 | — | — | US | disclosed |
| US-6489314-B1 | DUE TO THE INCREASING INTEREST IN EPOTHILONES AS ANTI-CANCER AGENTS, NOVEL DERIVATIVES OF THESE COMPOUNDS ARE NEEDED AND DESIRED TO MORE FULLY DEVELOP THEIR THERAPEUTIC POTENTIAL | KOSAN BIOSCIENCES, INC. | 2002-12-03 | — | — | US | disclosed |
| WO-2002080846-A2 | EPOTHILONE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME | KOSAN BIOSCIENCES, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-4948796-A | TREATING CEREBO-VASCULARE DISEASES | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | SMN1; SMN2 4832/4885NPC1 3237/4885RAB9A 67/4885 |
| US-20220411440-A1 | GLYCOSIDASE INHIBITORS | GAA, ENGASE, GBA3 | SMN1; SMN2 858/4885NPC1 386/4885RAB9A 730/4885 |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | SMN1; SMN2 103/4885NPC1 1281/4885RAB9A 2809/4885 |
| US-20030045711-A1 | Epothilone derivatives and methods for making and using the same | EPOR, SRD5A1, SRD5A2 | SMN1; SMN2 2555/4885NPC1 658/4885RAB9A 2325/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | SMN1; SMN2 858/4885NPC1 386/4885RAB9A 730/4885 |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | SMN1; SMN2 4165/4885NPC1 1513/4885RAB9A 1645/4885 |
| US-20020193361-A1 | Epothilone derivatives and methods for making and using the same | DHCR7, CBR1, NR3C2 | SMN1; SMN2 4151/4885NPC1 446/4885RAB9A 3941/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | SMN1; SMN2 858/4885NPC1 386/4885RAB9A 730/4885 |
| US-20050038086-A1 | Epothilone derivatives and methods for making and using the same | EPOR, CCNA1, CCNY | SMN1; SMN2 2701/4885NPC1 1011/4885RAB9A 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.